A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate)

This study has suspended participant recruitment.
(Clinical Hold)
Sponsor:
Collaborators:
The Cleveland Clinic
Duke Clinical Research Institute
Canadian VIGOUR Centre
Mount Sinai School of Medicine
Parexel
Information provided by (Responsible Party):
Regado Biosciences, Inc.
ClinicalTrials.gov Identifier:
NCT01848106
First received: May 2, 2013
Last updated: July 9, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)